skip to main content
OSTI.GOV title logo U.S. Department of Energy
Office of Scientific and Technical Information

Title: Id-1 gene and gene products as therapeutic targets for treatment of breast cancer and other types of carcinoma

Patent ·
OSTI ID:1150642

A method for treatment of breast cancer and other types of cancer. The method comprises targeting and modulating Id-1 gene expression, if any, for the Id-1 gene, or gene products in breast or other epithelial cancers in a patient by delivering products that modulate Id-1 gene expression. When expressed, Id-1 gene is a prognostic indicator that cancer cells are invasive and metastatic.

Research Organization:
Lawrence Berkeley National Laboratory (LBNL), Berkeley, CA (United States)
Sponsoring Organization:
USDOE
DOE Contract Number:
AC03-765F00098
Assignee:
California Pacific Medical Center Research Institute (San Francisco, CA); The Regents of the University of California (Oakland, CA)
Patent Number(s):
8,809291
Application Number:
13/252,148
OSTI ID:
1150642
Country of Publication:
United States
Language:
English

References (4)

Antisense modulation of inhibitor of DNA binding-1 expression patent April 2002
The helix-loop-helix transcription factor, Id-1, is overexpressed in medullary thyroid cancer journal December 2000
Id-1 and Id-2 Are Overexpressed in Pancreatic Cancer and in Dysplastic Lesions in Chronic Pancreatitis journal September 1999
A Novel Pathway for Mammary Epithelial Cell Invasion Induced by the Helix-Loop-Helix Protein Id-1 journal August 1998